Table 1.
Baseline characteristics of our study population stratified by glycaemic status according to OGTT results (ADA criteria)
| Characteristic | Available data | NGT | Prediabetes (IFG/IGT) | Diabetes | p-value | Known diabetes |
|---|---|---|---|---|---|---|
| Study population—no known diabetes, n = 841 | 139 (16.5%) | 398 (47.3%) | 304 (36.2%) | 433 | ||
| Age—yr [median (IQR)] | 841/841 | 63 (54–69) | 64 (58–71) | 66 (58–71) | 0.019 | 68 (61–75) |
| Gender (male) | 841/841 | 104 (74.8%) | 304 (76.4%) | 212 (69.7%) | 0.133 | 314 (72.5%) |
| Body-mass index [median (IQR)] | 796/841 | 25 (23–28) | 27 (24–30) | 28 (25–30) | < 0.001 | 28 (26–32) |
| Smokers | 801/841 | 38 (29.5%) | 142 (37.3%) | 118 (40.5%) | 0.054 | 84 (21.9%) |
| Snuff users | 560/841 | 2 (2.0%) | 23 (8.4%) | 12 (6.5%) | 0.083 | 9 (3.5%) |
| eGFR (mL/min/1.73 m2)—MDRD equation [median (IQR)] | 769/841 | 81 (69–89) | 83 (72–97) | 83 (70–96) | 0.177 | 73 (55–92) |
| Medical history | ||||||
| Previous myocardial infarction | 841/841 | 40 (28.8%) | 101 (25.4%) | 63 (20.7%) | 0.143 | 103 (23.8%) |
| Hypertension | 841/841 | 36 (25.9%) | 88 (22.1%) | 71 (23.4%) | 0.658 | 179 (41.3%) |
| Heart failure | 841/841 | 3 (2.2%) | 5 (1.3%) | 3 (1.0%) | 0.598 | 14 (3.2%) |
| Atrial fibrillation | 841/841 | 8 (5.8%) | 14 (3.5%) | 13 (4.3%) | 0.520 | 26 (6.0%) |
| Previous PCI or CABG | 841/841 | 32 (23.0%) | 84 (21.1%) | 58 (19.1%) | 0.612 | 83 (19.2%) |
| Stroke | 841/841 | 5 (3.6%) | 8 (2.0%) | 12 (3.9%) | 0.291 | 23 (5.3%) |
| Peripheral artery disease | 841/841 | 2 (1.4%) | 6 (1.5%) | 3 (1.0%) | 0.825 | 13 (3.0%) |
| Chronic kidney disease | 841/841 | 2 (1.4%) | 2 (0.5%) | 2 (0.7%) | 0.523 | 14 (3.2%) |
| Chronic obstructive pulmonary disease | 841/841 | 3 (2.2%) | 3 (0.8%) | 3 (1.0%) | 0.377 | 8 (1.8%) |
| Medications on discharge | ||||||
| Aspirin | 841/841 | 121 (87.1%) | 342 (85.9%) | 246 (80.9%) | 0.121 | 280 (64.7%) |
| Clopidogrel | 841/841 | 79 (56.8%) | 225 (56.5%) | 188 (61.8%) | 0.334 | 190 (43.9%) |
| Ticagrelor | 841/841 | 44 (31.7%) | 95 (23.9%) | 46 (15.1%) | < 0.001 | 56 (12.9%) |
| Prasugrel | 841/841 | 0 (0%) | 4 (1.0%) | 3 (1.0%) | 0.497 | 8 (1.9%) |
| ACE-inhibitors | 841/841 | 89 (64.0%) | 257 (64.6%) | 189 (62.2%) | 0.802 | 202 (46.7%) |
| ARB | 841/841 | 25 (18.0%) | 65 (16.3%) | 54 (17.8%) | 0.845 | 95 (21.9%) |
| Beta-receptor blockers | 841/841 | 126 (90.7%) | 341 (85.7%) | 251 (82.6%) | 0.08 | 277 (64.0%) |
| Statins | 841/841 | 122 (87.8%) | 342 (85.9%) | 252 (82.9%) | 0.338 | 271 (62.6%) |
| Dihydropyridines | 841/841 | 22 (15.8%) | 70 (17.6%) | 69 (22.7%) | 0.129 | 111 (25.6%) |
| Diuretics | 841/841 | 15 (10.8%) | 65 (16.3%) | 59 (19.4%) | 0.076 | 101 (23.3%) |
| Warfarin | 841/841 | 7 (5.0%) | 21 (5.3%) | 14 (4.6%) | 0.921 | 29 (6.7%) |